New Active Substance Launches Plummet
This article was originally published in SRA
The number of new active substances (NASs) launched in 2015 fell by nearly a third compared with the previous year. But there is no need for despair - beating 2014's record-breaking year of 63 NAS launches was always going to be a tall order, and 2015's tally actually came in at a very respectable 46.
You may also be interested in...
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.